NDLI: MTOR Pathway As a Potential Target In a Subset of Human Medulloblastoma

Content Provider	Springer Nature Link
Author	Pócza, Tímea Sebestyén, Anna Turányi, Eszter Krenács, Tibor Márk, Ágnes Sticz, Tamás Béla Jakab, Zsuzsanna Hauser, Péter
Copyright Year	2014
Abstract	As mammalian Target of Rapamycin (mTOR) plays role in protein synthesis and metabolism, mTOR pathway activation is involved in the pathogenesis of several types of tumors. Our aim was to elucidate its role in medulloblastoma in terms of prognosis and as a therapeutic target. Members of activated mTOR complex 1 (mTORC1) pathway, phospho-mTOR (p-mTOR) and phospho-S6 (p-S6) were examined by immunohistochemistry in formalin fixed paraffin embedded samples of 40 patients with medulloblastoma, and results were compared to clinical features and survival of patients. In proliferation assays, Daoy and UW228–2 medulloblastoma cell lines were tested by rapamycin, an mTORC1 inhibitor, and NVP-BEZ235, a dual mTOR and phosphatidylinositol 3-kinase (PI3K) inhibitor, each in monotherapy and in combination with cytostatic drugs (cisplatin, etoposide). Components of mTORC1 and mTORC2 complexes were also examined in these cell lines. Neither presence of p-mTOR (32.5 %) nor p-S6 (32.5 %) correlated with age, gender or histological subtype. In 22.5 % of cases simultaneous expression of p-mTOR and p-S6 was shown. Kaplan-Meier analysis showed inferior survival of patients expressing both marker proteins, but it was not statistically significant, probably due to low case number. UW228–2 cells had greater sensitivity to mTOR inhibitors, possibly due to its higher mTORC1 specific protein expression levels, compared to Daoy cells. In both cell lines antiproliferative effect of cytostatic drugs was significantly enhanced by mTOR inhibitors (p < 0.05). Based on our in vitro and clinicopathological studies mTOR inhibitors may have a role in the future treatment of a subset of patients with medulloblastoma.
Starting Page	893
Ending Page	900
Page Count	8
File Format	PDF
ISSN	12194956
Journal	Pathology & Oncology Research
Volume Number	20
Issue Number	4
e-ISSN	15322807
Language	English
Publisher	Springer Netherlands
Publisher Date	2014-04-16
Publisher Place	Dordrecht
Access Restriction	Subscribed
Subject Keyword	Medulloblastoma mTORC1 mTOR inhibitors Survival Daoy Pediatric Brain Tumor Rapamycin Cancer Research Oncology Pathology Immunology Biomedicine general
Content Type	Text
Resource Type	Article
Subject	Cancer Research Pathology and Forensic Medicine Oncology

Sl.	Authority	Responsibilities	Communication Details
1	Ministry of Education (GoI), Department of Higher Education	Sanctioning Authority	https://www.education.gov.in/ict-initiatives
2	Indian Institute of Technology Kharagpur	Host Institute of the Project: The host institute of the project is responsible for providing infrastructure support and hosting the project	https://www.iitkgp.ac.in
3	National Digital Library of India Office, Indian Institute of Technology Kharagpur	The administrative and infrastructural headquarters of the project	Dr. B. Sutradhar bsutra@ndl.gov.in
4	Project PI / Joint PI	Principal Investigator and Joint Principal Investigators of the project	Dr. B. Sutradhar bsutra@ndl.gov.in Prof. Saswat Chakrabarti will be added soon
5	Website/Portal (Helpdesk)	Queries regarding NDLI and its services	support@ndl.gov.in
6	Contents and Copyright Issues	Queries related to content curation and copyright issues	content@ndl.gov.in
7	National Digital Library of India Club (NDLI Club)	Queries related to NDLI Club formation, support, user awareness program, seminar/symposium, collaboration, social media, promotion, and outreach	clubsupport@ndl.gov.in
8	Digital Preservation Centre (DPC)	Assistance with digitizing and archiving copyright-free printed books	dpc@ndl.gov.in
9	IDR Setup or Support	Queries related to establishment and support of Institutional Digital Repository (IDR) and IDR workshops	idr@ndl.gov.in

Survivin Expression in Medulloblastoma: A Possible Marker for Survival

Anti-Tumor Effect of the Mammalian Target of Rapamycin Inhibitor Everolimus in Oral Squamous Cell Carcinoma

mTOR pathway as a potential target in a subset of human medulloblastoma.

Lack of Prognostic Significance of Survivin in Pediatric Medulloblastoma

Recent advances and limitations of mTOR inhibitors in the treatment of cancer

Extracellular Matrix Metalloproteinase Inducer is a Negative Prognostic Factor of Pediatric Medulloblastoma

Angiogenesis and Angiogenic Tyrosine Kinase Receptor Expression in Pediatric Brain Tumors

Role of mTOR in solid tumor systems: a therapeutical target against primary tumor growth, metastases, and angiogenesis

Expression Pattern of Id Proteins in Medulloblastoma

MTOR Pathway As a Potential Target In a Subset of Human Medulloblastoma

Similar Documents

Survivin Expression in Medulloblastoma: A Possible Marker for Survival

Anti-Tumor Effect of the Mammalian Target of Rapamycin Inhibitor Everolimus in Oral Squamous Cell Carcinoma

mTOR pathway as a potential target in a subset of human medulloblastoma.

Lack of Prognostic Significance of Survivin in Pediatric Medulloblastoma

Recent advances and limitations of mTOR inhibitors in the treatment of cancer

Extracellular Matrix Metalloproteinase Inducer is a Negative Prognostic Factor of Pediatric Medulloblastoma

Angiogenesis and Angiogenic Tyrosine Kinase Receptor Expression in Pediatric Brain Tumors

Role of mTOR in solid tumor systems: a therapeutical target against primary tumor growth, metastases, and angiogenesis

Expression Pattern of Id Proteins in Medulloblastoma

MTOR Pathway As a Potential Target In a Subset of Human Medulloblastoma